Gene and cell therapies targeting central nervous system (CNS) disorders involve modifying genes or grafting specific cells to treat various neurological conditions. These therapies work by delivering functional copies of missing or mutated genes to compensate for genetic defects, or by providing cells to replace those lost or damaged due to disease or injury.
The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 9.45 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Gene and Cell Therapies Targeting CNS Disorders are Byucksan, Great Lakes Textiles, ISOVER (Saint Gobain), mJohns Manville, Knauf Insulation, National Industrial Co., NTN OOD, Owens Corning, PGF Insulation, Rockwool International AS, Kingspan Group, and Rosewool Insulation Refractory Co. Ltd. Growing prevalence of neurological disorders such as Alzheimer's, Parkinson's and various forms of epilepsy is expected to drive the demand for effective treatment options. Emergence of newer gene therapy techniques such as CRISPR-Cas9 genome editing is also fueling the development of novel therapies for CNS conditions.
Market Trends
Increasing consolidation activity: Leading players in the market are pursuing partnerships and acquisitions to gain access to newer technologies and expand their product portfolios. For instance, Novartis acquired AveXis for $8.7 billion in 2018 to strengthen its gene therapy pipeline.
Focus on regenerative therapies: Many companies are investing in stem cell and tissue engineering research with the goal of developing regenerative treatments that can reverse damage caused by diseases. Axovant Gene Therapies is exploring intrathecal administration of gene therapies for brain disorders.
Market Opportunities
Untapped potential in Asia Pacific: Countries like China and India offer lucrative opportunities for gene and cell therapy providers given the huge patient populations and improving healthcare investments in these markets.
Multi-indication therapies: Development of "platform technologies" that can potentially treat a whole range of related conditions presents a major commercial opportunity. Companies are pursuing this approach to target broader disease categories.
Impact of COVID-19 on Gene and Cell Therapies Targeting CNS Disorders Market Growth
The COVID-19 pandemic has impacted the growth of the Gene And Cell Therapies Targeting CNS Disorders Market Demand During the initial months of the pandemic in 2020, clinical trials and other research activities were disrupted due to lockdowns and social distancing measures imposed worldwide. This led to delays in the development of new therapies and products in the market. It also affected the supply chain and distribution channels as international trade was stalled. However, with resumption of activities in 2021, the market is recovering gradually. Companies are focusing on digital technologies like telehealth to continue patient engagement and education programs. Governments are also prioritizing funding for CNS disorder research to develop advanced treatment options. It is expected that focus on gene and cell therapy development will increase in the coming years to address the growing patient population of neurological conditions like Parkinson's disease, Alzheimer's disease, etc.
In terms of geographical concentration, North America holds the major share of the global gene and cell therapies targeting CNS disorders market in terms of value. This is attributed to the presence of large healthcare companies engaged in research and development activities for these advanced therapies. The United States dominates the North American market due to availability of reimbursement and support from private and public research funding. Europe is the second largest regional market supported by initiatives from bodies like the European Medical Agency to promote cell and gene therapy development. The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to rising healthcare expenditure, increasing incidence of neurological disorders, and developing research infrastructure in major countries like China and India.
Get more insights, On Gene And Cell Therapies Targeting CNS Disorders Market
